Last reviewed · How we verify
Welchol
At a glance
| Generic name | Welchol |
|---|---|
| Sponsor | Daiichi Sankyo |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Hypercholesterolemia
- Type 2 Diabetes Mellitus Treatment Adjunct
Common side effects
- Constipation
- Dyspepsia
- Nausea
- Headache
- Nasopharyngitis
- Upper respiratory tract infection
- Influenza
- Abdominal pain
Serious adverse events
- Body rash and mouth blistering (possible hypersensitivity reaction)
Key clinical trials
- Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE) (PHASE1, PHASE2)
- A Study of Colesevelam for Lenalidomide-Associated Diarrhea (PHASE2)
- Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
- Metabolic Effects of Endogenous Bile Acids After Gastric Bypass Surgery (EARLY_PHASE1)
- Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib (PHASE2)
- Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation. (PHASE1, PHASE2)
- A Study of Colesevelam in Fecal Incontinence (PHASE3)
- Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Welchol CI brief — competitive landscape report
- Welchol updates RSS · CI watch RSS
- Daiichi Sankyo portfolio CI